Negative inotropic effects of recombinant interleukin 2 in patients without left ventricular dysfunction

European Journal of Heart Failure

Volumn 2, Issue 2, 2000, Pages 167-173

  Tio, René A ^a   Nieken, Judith ^a   De Vries, Elisabeth G E ^a   Pfeiffer, Carolein ^a   De Jongste, Mike J L ^a   Pieper, Els ^a   Moshage, Han ^b   Limburg, Piet C ^a   Mulder, Nanno H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Heart failure; Heart rate variability; Interleukin 2; Nitric oxide

Indexed keywords

NITRATE; NITRIC OXIDE; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; FEVER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE VARIABILITY; HUMAN; INFLAMMATION; INOTROPISM; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; SYMPATHETIC TONE;

ADULT; AGED; AUTONOMIC NERVOUS SYSTEM; CARCINOMA, RENAL CELL; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART RATE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 0034123396     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(00)00073-8     Document Type: Article

References (32)

1. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
2. Finkel M.S., Hoffman R.A., Shen L., Oddis C.V., Simmons R.L., Hattler B.G. Interleukin-6 (IL-6) as a mediator of stunned myocardium. Am J Cardiol. 71:1993;1231-1232.
3. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
4. Fuchs D., Samsonov M., Tilz G.P. et al. Stimulated cellular immune system in patients with congestive heart failure. Eur J Clin Chem Clin Biochem. 31:1993;111-114.
5. Koike S. Immunological disorders in patients with dilated cardiomyopathy. With special reference to the production of interleukin-2 and the expression of interleukin-2 receptors in the patients' peripheral blood lymphocytes. Jpn Heart J. 30:1989;799-807.
6. Kolbeck P.C., Steenbergen C., Wolfe J.A., Sanfilippo F., Jennings R.B. The correlation of mononuclear cell phenotype in endomyocardial biopsies with clinical history and cardiac dysfunction. Am J Clin Pathol. 91:1989;37-44.
7. Rosenberg S.A., Yang J.C., Topalian S.L. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Ann Intern Med. 271:1994;907-913.
8. Fisher R.I., Coltman C.A., Doroshow J.H. et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 108:1988;518-523.
9. West W.H. Clinical application of continuous infusion of recombinant interleukin-2. Eur J Cancer Clin Oncol. 25(3):1989;S11-S15.
10. Ognibene F.P., Rosenberg S.A., Lotze M. et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest. 94:1988;750-754.
11. Osanto S., Cluitmans F.H., Franks C.R., Bosker H.A., Cleton F. Myocardial injury after interleukin-2 therapy (letter). Lancet. 2:1988;9.
12. Gaynor E.R., Vitek L., Sticklin L. et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 109:1988;953-958.
13. Anonymous. WHO Handbook for reporting results in cancer treatment, offset publication 48. Geneva Switzerland World Health Organization.
14. Heart rate variability: standards of measurement, physiologic interpretation and clinical use. Circulation. 93:1996;1043-1065.
15. van der Zee A.G., de Cuyper E.M., Limburg P.C. et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 75:1995;1004-1009.
16. Kukielka G.L., Smith C.W., Manning A.M., Youker K.A., Michael L.H., Entman M.L. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation. 92:1995;1866-1875.
17. Rabinovici R., Feuerstein G., Abdullah F. et al. Locally produced tumor necrosis factor-alpha mediates interleukin-2- induced lung injury. Circ Res. 78:1996;329-336.
18. Kasahara T., Hooks J.J., Dougherty S.F., Oppenheim J.J. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol. 130:1983;1784-1789.
19. Numerof R.P., Aronson F.R., Mier J.W. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol. 141:1988;4250-4257.
20. Mier J.W., Vachino G., Klempner M.S. et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood. 76:1990;1933-1940.
21. Luss H., Watkins S.C., Freeswick P.D. et al. Characterization of inducible nitric oxide synthase expression in endotoxemic rat cardiac myocytes in vivo and following cytokine exposure in vitro. J Mol Cell Cardiol. 27:1995;2015-2029.
22. Singh K., Balligand J.L., Fischer T.A., Smith T.W., Kelly R.A. Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells. Role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha. J Biol Chem. 271:1996;1111-1117.
23. Hung J., Kelly D.T., Hutton B.F., Uther J.B., Baird D.K. Influence of heart rate and atrial transport on left ventricular volume and function: relation to hemodynamic changes produced by supraventricular arrhythmia. Am J Cardiol. 48:1981;632-638.
24. Rozenman Y., Weiss A.T., Atlan H., Gotsman M.S. Left ventricular volumes and function during atrial pacing in coronary artery disease a radionuclide angiographic study. Am J Cardiol. 53:1984;497-502.
25. Erbel R, Schweizer P, Krebs W, Langen H.J., Meyer J, Effert S. Effects of heart rate changes on left ventricular volume and ejection fraction: a 2-dimensional echocardiographic study. Am J Cardiol. 53:1984;590-597.
26. Sobotka P.A., McMannis J., Fisher R.I., Stein D.G., Thomas J.X. Effects of interleukin 2 on cardiac function in the isolated rat heart. J Clin Invest. 86:1990;845-850.
27. Citterio G., Fragasso G., Rosetti E. et al. Isolated left ventricular filling abnormalities may predict interleukin-2-induced cardiovascular toxicity. J Immunother Emphasis Tumor Immunol. 19:1997;134-141.
28. Rogausch H., Del Rey A., Kabiersch A., Besedovsky H.O. Interleukin-1 increases splenic blood flow by affecting the sympathetic vasoconstrictor tonus. Am J Physiol. 268:1995;R902-R908.
29. Soliven B., Wang N. Tumor necrosis factor-alpha regulates nicotinic responses in mixed cultures of sympathetic neurons and nonneuronal cells. J Neurochem. 64:1995;883-894.
30. Blay J.Y., Favrot M.C., Negrier S. et al. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res. 50:1990;2371-2374.
31. Boccoli G., Masciulli R., Ruggeri E.M. et al. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res. 50:1990;5795-5800.
32. Citterio G., Pellegatta F., Lucca G.D. et al. Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2. Br J Cancer. 74:1996;1297-1301.